Table 1.
Characteristics of 10 patients with recurrent unresectable hepatocellular carcinoma after liver transplantation.
| Patient Number | Age/Sex | Body Weight (kg) | ECOG PS | Child-Pugh Classification | BCLC Classification | Viral Hepatitis Status | Immunosuppressant Agents | Duration from LT to Tumor Recurrence (Months) | Recurrent Status | Extrahepatic Spread at the Time of Recurrence | Metastatic Site at the Time of Recurrence | Duration of Prior Sorafenib (Months) | Best Response to Sorafenib | Main PVT at the Time of Lenvatinib | Macrovascular Invasion at the Time of Lenvatinib | Extrahepatic Spread at the Time of Lenvatinib | Metastatic Site at the Time of Lenvatinib | LN Involvement at the Time of Lenvatinib | AFP at the Time of Lenvatinib | Best Response to Lenvatinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 39/M | 67.0 | 0 | A | C | hepatitis B | Everolimus Tacrolimus Prolonged-release |
22.0 | Hepatic combined with extrahepatic | Yes | Regional lymph nodes | 4.6 | PR | No | No | Yes | Regional lymph nodes | Yes | <2.0 | PR |
| 2 | 37/M | 65.7 | 1 | A | C | hepatitis B | Sirolimus Tacrolimus (FK506) |
49.2 | Extrahepatic | Yes | lung | 3.0 | SD | No | No | Yes | Lung and regional lymph nodes | Yes | 3.8 | SD |
| 3 | 54/M | 66.6 | 1 | A | C | hepatitis B | Tacrolimus (FK506) Sirolimus |
10.2 | Hepatic combined with extrahepatic | Yes | lung | 30.7 | PR | No | No | Yes | Lung | No | 78.2 | SD |
| 4 | 62/M | 78.2 | 1 | A | C | hepatitis B | Tacrolimus (FK506) | 18.3 | Extrahepatic | Yes | bone | 3.1 | SD | No | No | Yes | Bone | No | <3.0 | SD |
| 5 | 63/M | 61.0 | 1 | A | C | hepatitis C | Everolimus Tacrolimus Prolonged-release |
23.4 | Extrahepatic | Yes | Peritoneal seeding | 2.5 | SD | No | No | Yes | Lung and peritoneal seeding | No | 196.1 | SD |
| 6 | 39/M | 67.6 | 0 | A | C | hepatitis B | Tacrolimus (FK506) Sirolimus |
14.9 | Hepatic combined with extrahepatic | Yes | lung | 5.1 | PD | No | No | Yes | Lung | No | 830.4 | PD |
| 7 | 58/M | 73.1 | 0 | A | C | hepatitis C | Sirolimus Mycophenolate mofetil |
54.2 | Extrahepatic | Yes | bone, lung | 18.9 | PR | No | No | Yes | Lung and bone | No | 2942.0 | PR |
| 8 | 49/M | 66.9 | 0 | A | C | hepatitis B | Everolimus Tacrolimus (FK506) |
34.0 | Extrahepatic | Yes | lung | 12.9 | SD | No | No | Yes | Lung | No | 2.7 | SD |
| 9 | 57/M | 63.5 | 1 | A | B | hepatitis C | Tacrolimus (FK506) Sirolimus |
13.8 | Hepatic | No | – | 4.7 | PD | No | No | No | – | No | 57.9 | PD |
| 10 | 57/M | 71.0 | 1 | A | C | hepatitis C | Tacrolimus (FK506) Mycophenolate mofetil |
13.0 | Extrahepatic | Yes | bone | 4.2 | PD | No | No | Yes | Bone | No | 46,142.3 | PD |
ECOG PS: Eastern Cooperative Oncology Group performance status; BCLC: Barcelona Clinic Liver Cancer; PVT: portal vein thrombosis; LT: liver transplantation; LN: lymph node; AFP: alpha-fetoprotein; PR: partial response; SD: stable disease; PD: progressive disease.